Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia

Authors not listed

Taipei Medical University WanFang Hospital · 2022

Abstract

Fucoidan also ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms in vivo and in vitro. To evaluate the effect of fucoidan in cancer cachexia or sarcopenia in cancer patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Anonymous. (2022). A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia. <em>Taipei Medical University WanFang Hospital</em>. https://clinicaltrials.gov/study/NCT05623852
Vancouver
Anonymous. A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia. Taipei Medical University WanFang Hospital. 2022.
BibTeX
@misc{anon2022APhase, title = {A Phase II Trial for Oligo-Fucoidan in Cancer Cachexia and Sarcopenia}, author = {Anonymous}, journal = {Taipei Medical University WanFang Hospital}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings